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Abstract
Objectives The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic 
lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative 
impact of critical parameters on incremental costs and quality-adjusted life-years (QALYs).
Methods A partitioned survival model was constructed comparing acalabrutinib and ibrutinib from a UK national health 
service perspective. This model included states for progression-free survival (PFS), post-progression survival (PPS) and 
death. PFS and overall survival (OS) were parametrically extrapolated from ibrutinib publications and a preliminary hazard 
ratio based on phase I/II data was applied for acalabrutinib. Deterministic and probabilistic sensitivity analyses were per-
formed, and 1296 scenarios were assessed.
Results The base-case incremental cost-effectiveness ratio (ICER) was £61,941/QALY, with 3.44 incremental QALYs and 
incremental costs of £213,339. Deterministic sensitivity analysis indicated that survival estimates, utilities and treatment 
costs of ibrutinib and acalabrutinib and resource use during PFS have the greatest influence on the ICER. Probabilistic results 
under different development scenarios indicated that greater efficacy of acalabrutinib would decrease the likelihood of cost 
effectiveness (from 63% at no effect to 2% at maximum efficacy). Scenario analyses showed that a reduction in PFS did not 
lead to great QALY differences (− 8 to − 14% incremental QALYs) although it did greatly affect costs (− 47 to − 122% 
incremental pounds). For OS, the opposite was true (− 89 to − 93% QALYs and − 7 to − 39% pounds).
Conclusions Acalabrutinib is not likely to be cost effective compared with ibrutinib under current development scenarios. 
The conflicting effects of OS, PFS, drug costs and utility during PFS show that determining the cost effectiveness of acala-
brutinib without insight into all parameters complicates health technology assessment decision making. Early assessment 
of the cost effectiveness of new products can support development choices and reimbursement processes through effective 
early dialogues between stakeholders.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 8-019-00496 -1) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Bruton’s tyrosine kinase (BTK) inhibitors represent a 
new line of treatment for chronic lymphocytic leukaemia 
(CLL), with drugs in development and one already on the 
market: ibrutinib. Ibrutinib has now been approved for pre-
viously treated and untreated CLL and has been shown to 
be clinically effective with a durable response [1–3]. How-
ever, ibrutinib is not entirely specific for BTK. It may also 
inhibit epidermal growth factor receptor (EGFR), interleu-
kin-2–inducible T cell kinase (ITK), T-cell X chromosome 
kinase, and tyrosine kinase expressed in hepatocellular car-
cinoma (TEC) family proteins, leading to side effects such as 
bleeding, atrial fibrillation, rash and diarrhoea [4–6].
A more specific BTK inhibitor showing promise in pre-
clinical and early clinical trials is acalabrutinib (ACP-196). 
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Key Points for Decision Makers 
Based on this model, even with a price equal to ibrutinib, 
acalabrutinib is not cost effective with a willingness-to-
pay threshold of £50,000. The probability of acalabruti-
nib being cost effective declines with greater efficacy.
Cost-effectiveness analyses for acalabrutinib lead to 
incentives to show a lack of progression-free survival 
benefit because the additional costs associated with 
prolonged progression-free survival are not offset by the 
additional quality-adjusted life-years gained.
The conflicting effects of quality of life and survival 
benefits disrupt proper assessment of the added value 
of acalabrutinib, which might lead to delays in patient 
access.
To get novel haematological agents to patients effectively 
and in a timely manner, development should include an 
early assessment of added value such as that presented 
here.
makers and manufacturers to streamline clinical develop-
ment and reimbursement processes [15–18].
The objective of this study was to construct, based on 
published phase I/II data, an early cost-utility analysis com-
paring acalabrutinib and ibrutinib for chronic lymphocytic 
leukaemia to assist early reimbursement decision making. 
Sensitivity analyses were performed, and possible develop-
ment scenarios were assessed, identifying critical parameters 
and quantifying their relative impact on incremental costs 
and QALYs.
2  Methods
2.1  General
An effectively lifetime partitioned survival model compar-
ing acalabrutinib and ibrutinib was constructed in Micro-
soft Excel (Microsoft, Redmond, WA, USA) from a UK 
national health service perspective. As portrayed in Fig. 1, 
included health states were progression-free survival (PFS), 
post-progression survival (PPS) and death. PPS was split 
into two sub-states: subsequent treatment (PPS-ST) and 
best supportive care (PPS-BSC). The modelled population 
was based on the only available phase I/II trial for acala-
brutinib and assumed representative for the UK relapsed 
CLL patient population [13]. The model was based on the 
NICE assessment of the manufacturer’s submission for 
ibrutinib, appraisal number TA429 [14]. Patients moved 
between health states in cycles of 28 days with a time hori-
zon of 30 years (effectively lifetime). Half-cycle corrections 
were applied. Costs and outcomes were both discounted by 
3.5%. The model was constructed according to International 
Society for Pharmacoeconomics and Outcomes Research 
good modelling practice, and method reporting follows the 
Fig. 1  Model structure
In preclinical research, acalabrutinib did not inhibit EGFR, 
TEC, ITK or other agents [7–10]. Like ibrutinib, acalabruti-
nib binds covalently to Cys481 in the adenosine triphosphate 
(ATP) binding pocket of BTK. It shows a rapid oral absorp-
tion with a short plasma half-life, theoretically leading to 
less toxicity [11, 12]. Early clinical studies with acalabruti-
nib showed overall response rates of 95% at median follow-
up of 14.3 months and mostly grade 1 or 2 adverse events 
without dose-limiting toxicity [13].
Based on these findings, acalabrutinib would be a valu-
able addition to the therapeutic options for CLL. However, 
patient access also relies on the decisions of health technol-
ogy assessment (HTA) bodies. In the UK, the National Insti-
tute for Health and Care Excellence (NICE) reported that 
ibrutinib’s initial price led to a base-case incremental cost-
effectiveness ratio (ICER) of £45,486 per quality-adjusted 
life-year (QALY) when compared with treatment with physi-
cians’ choice [14]. They advised to reimburse ibrutinib only 
if the negotiated (confidential) discount would be upheld. 
Such evaluations by HTA bodies and concomitant price 
negotiations can take up to a year, delaying patient access.
To reduce delays in patient access, it is possible to start 
early with the assessment of added value of a new therapy. 
This can start during preclinical development but is more 
regularly executed during phase I or II clinical trials. One 
method is the use of early cost-utility analyses, which can 
clarify the relative impact of the parameters that drive cost 
effectiveness. Early cost-utility analyses allow decision 
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Consolidated Health Economic Evaluation Reporting Stand-
ards statement for reporting standards [19].
2.2  Treatment, Comparator and Subsequent 
Treatment
Ibrutinib 420 mg/day (three capsules) is administered until 
disease progression or until no longer tolerated by the 
patient. Acalabrutinib is given as 200 mg/day (two cap-
sules). After progression, 41.9% of patients receive subse-
quent treatment. Subsequent treatment consists of rituximab 
and idelalisib. Rituximab is given in six cycles of 4 weeks, 
with an initial dose of 375 mg/m2 and subsequent doses 
of 500 mg/m2, according to the NICE guideline for CLL 
[20]. Idelalisib is administered until disease progression or 
death in a dose of 150 mg twice daily. A dose intensity of 
94.8% was applied for acalabrutinib, ibrutinib and idelalisib, 
in accordance with findings from the RESONATE trial [2, 
14]. In this study, acalabrutinib was assessed relative only 
to its primary comparator from the same class within the 
same indication (ibrutinib), as this is expected to be the main 
competitor in practice. Ofatumumab, physician’s choice or 
other treatment regimens were not assessed in this study.
2.3  Survival Data
The efficacy of ibrutinib was established in a phase III mul-
ticentre, open-label, randomised clinical trial comparing it 
with ofatumumab [2]. The preliminary efficacy of acalabru-
tinib was established in a multicentre, open-label, single-arm 
phase I/II trial [13].
PFS and OS individual patient data for ibrutinib was 
reconstructed from the reported Kaplan–Meier curves [21]. 
Multiple parametric survival curves were tested: an expo-
nential, Weibull, log-logistic and lognormal distribution. 
The exponential curve showed physiological plausibility and 
overall best fit for OS as well as PFS, corresponding with 
the expert review group comments on the ibrutinib submis-
sion for NICE [14]. For acalabrutinib, efficacy compared 
with ibrutinib was established through an indirect treatment 
comparison based on the extracted individual patient data, 
providing a hazard ratio (HR) of 0.479 for PFS (95% con-
fidence interval [CI] 0.230–0.998) and 0.391 for OS (95% 
CI 0.141–1.081). Because these are based on very limited 
data, we set the range of variation in sensitivity and sce-
nario analyses for these HRs from 0.479 and 0.391 to 1.00, 
representing the full range up until no benefit for acalabru-
tinib. Furthermore, no assumptions were made about the 
distribution of this effect. The base case (which equals the 
maximum HR) was tested (0.479 and 0.391 for PFS and OS, 
respectively) as were five uniform steps up until no benefit, 
resulting in six scenarios for the HRs (base case/maximum, 
80%, 60%, 40%, 20% and no benefit). In the probabilistic 
sensitivity analysis (PSA), the base assumption was that OS 
and PFS were independent. To test the effect of this assump-
tion, the six scenarios for the PSA were also implemented, 
with the OS and PFS sharing the same random number when 
sampled, creating dependence. The full survival calcula-
tions, fitting criteria and ranges for all parametric models are 
provided in the Electronic Supplementary Material (ESM) 1.
PPS is defined as OS minus PFS and comprises patients 
receiving subsequent treatment as well as patients receiving 
best supportive care. PPS-ST was implemented by plotting 
a Weibull curve from the PFS given in the Kaplan–Meier 
graph provided by Furman et al. [22]. The Weibull curve was 
chosen because NICE evaluated it as being the most suited 
curve for this treatment. In this multicentre, randomised, 
double-blind, placebo-controlled, phase III study, the effi-
cacy of rituximab and idelalisib combination therapy was 
assessed in patients with relapsed CLL [22]. After 80 cycles 
(75 months), Weibull plotted survival was < 0.01% and 
therefore assumed to be 0. Because transition probabilities to 
the PPS state are not explicitly modelled in a partitioned sur-
vival model, entry into the PPS state each cycle was calcu-
lated by subtracting a specific background mortality from the 
proportion of patients leaving PFS. This background mor-
tality was retrieved from the Life Expectancy Tables from 
the Office for National Statistics [23]. This method was also 
used in the ibrutinib submission; however, the background 
mortality was considered fixed, whereas ours increased with 
increasing age.
2.4  Costs and Resource Use
Unit costs for the drug treatments were provided by the Brit-
ish National Formulary [24]. All costs are reported in UK 
pound sterling (£), year 2018 values. When cost inputs were 
based on different years, they were inflated with the Hospital 
and Community Health Services Pay and Price Index and, 
after discontinuation of this index in 2017, with the health-
specific subset of the consumer price inflation index [25]. 
Daily costs for acalabrutinib treatment were assumed equal 
to ibrutinib in the base-case and sensitivity analyses and 
varied through scenario analyses, testing for 30% pricing 
premiums and reductions (Table 1). Costs for rituximab are 
only inflicted in the first six cycles of subsequent treatment, 
in accordance with its approved indication, and are based 
on an average body surface area of 1.9 m2 [14]. Full calcu-
lations for costs per cycle of treatment with acalabrutinib, 
ibrutinib and rituximab + idelalisib are provided in ESM 2.
Costs of grade 3 and 4 adverse events (AEs) were 
included according to the UK national schedule of reference 
costs 2015–2016 [26]. Incidences were implemented from 
clinical trials for acalabrutinib and from the NICE ibrutinib 
assessment [13, 14]. AE costs were inflicted once, in the first 
cycle. This matched the approach used in the NICE ibrutinib 
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submission and is supported by the fact that onset of side 
effects was generally within the first half year and the dura-
tion of side effects was short [2, 14].
Annual healthcare resource use such as hospital visits 
or blood tests associated with routine follow-up care was 
included. Resource use is based on expert elicitation reported 
by the manufacturer in the ibrutinib submission and differs 
per model state (PFS, PPS-ST, PPS-BSC) and whether the 
patient in the PFS state was a complete responder (CR), par-
tial responder (PR) or non-responder (NR, including stable 
Table 1  Input parameters and 
their  rangesa
OS overall survival, PFS progression-free survival, PPS post-progression survival, PPS-BSC post-progres-
sion survival on best supportive care, PPS-ST post-progression survival on subsequent treatment, ST subse-
quent treatment
a Calculations are presented in the Electronic Supplementary Material 1–4
Parameter Base Minimum Maximum Distribution Source
Mean age 62 Fixed [13]
Mean body surface area  (m2) 1.9 Fixed
Time horizon (years) 30 Fixed NA
Discount rates
 Costs 0.035 Fixed [25]
 Effects 0.035 Fixed [25]
Utilities
 PFS
  Acalabrutinib 0.799 0.799 0.837 Beta [2, 14]
  Ibrutinib 0.799 0.799 0.837 Beta [2, 14]
 PPS 0.701 0.631 0.771 Beta [2, 14]
 Adverse event disutility
  Acalabrutinib 0.065 0.058 0.071 Beta [13, 14]
  Ibrutinib 0.091 0.082 0.100 Beta [1, 2, 14]
Costs (£)
 Treatment during PFS
  Acalabrutinib 4279 2996 5563 Fixed [14]
  Ibrutinib 4279 2996 5563 Fixed [14]
 Adverse events
  Acalabrutinib 639 319 958 Normal [13, 14]
  Ibrutinib 829 414 1243 Normal [1, 2, 14]
 PFS state
  Acalabrutinib 244 122 367 Normal [14]
  Ibrutinib 245 122 367 Normal [14]
 PPS state
  Rituximab + idelalisib cycle 1–6 5428 1206 7137 Normal [20, 23]
  Rituximab + idelalisib cycle 7+ 3298 780 4368 Normal [20, 23]
  BSC 177 88 265 Normal [14]
  Death 3051 1525 4576 Normal [26]
Survival parameters
 Ibrutinib (hazard rates)
  PFS 0.013 0.018 0.010 Normal [2]
  OS 0.008 0.010 0.006 Normal [2]
 Acalabrutinib (hazard ratios)
  PFS 0.479 1.000 0.479 6 steps [13]
  OS 0.391 1.000 0.391 6 steps [13]
 ST (Weibull)
  Scale 0.008 0.008 0.008 Fixed [22]
  Shape 1.582 1.758 1.439 Fixed [22]
 Percentage receiving ST 0.419 0.219 0.619 Normal [14]
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disease and progressive disease). Treatment responses for 
ibrutinib were reported to be 84% PR, 6% CR and 10% NR. 
For acalabrutinib, 95% were PR and 5% were NR [13, 14]. 
Full calculations of AE costs and resource use per treatment 
are provided in ESM 3.
Costs for the death state were inflicted once in the cycle 
when death happened and equal the per patient costs of 
healthcare utilisation during the last 30 days of life for 
patients aged ≥ 65 years with any cancer reported by Bekel-
man et al. [27]. Costs and ranges for sensitivity analyses are 
stated in Table 1.
2.5  Utilities
Utility for acalabrutinib was not available and was therefore 
assumed equal to the ibrutinib utility of 0.799 reported in the 
RESONATE trial, as measured by the five-level EuroQoL-5 
Dimensions (EQ-5D-5L). UK weights were used to generate 
patient utilities [14]. As an optimum utility for sensitivity 
and scenario analyses, utility was calculated according to 
utilities awarded to the response states [28]. AE disutility 
was calculated according to the incidence and utility dec-
rement of AEs reported in clinical trials for ibrutinib and 
acalabrutinib [1, 2, 13]. As with AE costs, disutility accord-
ing to AEs was inflicted once, in the first cycle. The full 
calculations for disutility due to AEs are provided in ESM 
4. To get the post-progression utility, the baseline utility was 
corrected for the reported utility decrement of 0.098 associ-
ated with progression [14]. Base-case utilities and ranges 
are provided in Table 1.
2.6  Sensitivity and Scenario Analyses
Uncertainties were assessed through sensitivity and sce-
nario analyses. In a one-way sensitivity analysis, the impact 
of each model input parameter was assessed individually 
according to their minimum and maximum value provided 
in Table 1. This deterministic sensitivity analysis shows 
the impact of the minimum and maximum values for each 
separate parameter on the ICER. Additionally, PSAs were 
performed for each of the six HR steps, thus testing cost 
effectiveness for different acalabrutinib efficacy scenarios. 
Body surface area and age were not varied in the PSA, in 
line with the ibrutinib submission.
From the deterministic analysis, important parameters 
were selected that had a profound influence on the ICER, 
defined by variations > 5% from the base-case ICER for 
the minimum and/or maximum scenario. For these critical 
parameters, all possible combinations of parameter values 
were tested in scenarios. This means that, for each value 
for each important parameter (the base-case, minimum and 
maximum values), all combinations of values for the other 
parameters were tested. This resulted in an overview of the 
impact of each parameter on incremental costs and QALYs. 
The calculation for this relative impact is given in ESM 5.
3  Results
The base-case ICER was £61,941/QALY, with 3.44 incre-
mental QALYs and incremental costs of £213,339. Abso-
lute costs and QALYs were £317,853 and 5.88 for ibrutinib 
and £531,192 and 9.33 for acalabrutinib, respectively. The 
one-way sensitivity analysis shown in Fig. 2 indicates that 
survival estimates, utilities and treatment costs of ibrutinib 
and acalabrutinib and resource use during PFS have a dis-
tinct influence on the ICER. As Fig. 2 also shows, OS and 
PFS have opposite effects, i.e. when OS for acalabrutinib is 
reduced, it increases the ICER, whereas reducing PFS leads 
to a smaller ICER. Higher utility and lower treatment and 
resource costs during PFS reduce the ICER. For ibrutinib, 
the opposite was true for all variables.
Results of the PSAs are shown in Fig. 3. When the effi-
cacy of acalabrutinib grew (HR further from 1.00), the incre-
mental costs and incremental QALYs both increased, but not 
simultaneously. With no effect (HRs PFS and OS = 1.00), the 
probability of cost effectiveness was 63% with a willingness-
to-pay (WTP) threshold of £50,000/QALY. This declined 
gradually from 42%, to 25%, 10%, 3% and 2% (HRs 20, 
40, 60, 80% and HR maximum, respectively). Thus, higher 
efficacy and the resulting higher QALYs led to dispropor-
tionately higher costs for acalabrutinib, when the price was 
equal to ibrutinib. Assuming dependence between PFS and 
OS did not lead to very different results. Mean ICERs were 
within ± 3% of mean ICERs without dependence. Probabili-
ties of cost effectiveness with a WTP threshold of £50,000/
QALY were 60%, 42%, 26%, 12%, 5% and 1% for HRs 1.00, 
20%, 40%, 60%, 80% and maximum, respectively.
3.1  Scenarios
The deterministic analysis provided ten parameters that 
explained most of the variation. Of those ten, resource use 
costs and treatment costs during PFS were perfectly corre-
lated with each other. Therefore, these were combined into 
one parameter (called costs acalabrutinib/ibrutinib) to reduce 
the number of scenarios. Eight parameters remained: four 
had base-case, minimum and maximum values (costs during 
PFS for both treatments and PFS and OS survival parameters 
for ibrutinib) and four had only two values (base-case and 
minimum [HRs for acalabrutinib] or base-case and maxi-
mum [utility during PFS for both treatments]). This led to a 
total of  34 × 24 = 1296 scenarios, which were all tested. For 
each parameter, the effect on incremental QALYs and incre-
mental costs in the minimum and/or maximum scenario ver-
sus the base-case scenario was calculated for all scenarios. 
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Fig. 2  Relative effects of individual parameters in comparison with 
the base-case incremental cost-effectiveness ratio of £61,941/quality-
adjusted life-year. Note that some parameters are only varied one way 
because the base case represents the maximum or minimum. acal 
acalabrutinib, AE adverse events, BSC best supportive care, C costs, 
ibru ibrutinib, OS overall survival, PFS progression-free survival, 
PPS post-progression survival, ST subsequent treatment, U utility
Fig. 3  Cost-effectiveness planes for different hazard ratios. The dark grey dot indicates the base case
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Figure 4 shows these effects for each of the included eight 
parameters. The size of the impact of a parameter on incre-
mental costs and QALYs depended on the scenario, i.e. the 
values of the other input parameters. Figure 4 shows all dis-
tinctive values for each parameter. The results indicate that 
OS was a main driver of incremental QALYs throughout all 
scenarios, but it does not impact on costs proportionally. The 
inverse was the case for PFS, which greatly affected costs 
but not QALYs proportionally.
A minimal OS of acalabrutinib led to a reduction in incre-
mental QALYs (89–93% of base-case QALYs) while not 
greatly influencing incremental cost (reduction of 7–39% 
of base-case costs), leading to a higher ICER. A minimal 
PFS led to smaller incremental costs (reduction of 47–122% 
of base-case costs) but did not significantly affect QALYs 
(reduction of 8–14% of base-case QALYs), leading to a 
smaller ICER. Effects of these parameters for ibrutinib were 
similar but had an opposite direction of effect (i.e. small 
PFS led to a greater ICER). Utility had a relatively minor 
effect. Incremental QALY benefits due to greater utility dur-
ing treatment (based on response rates as described in the 
Methods section) are relatively small throughout all scenar-
ios (4.5–9.7% of base case). QALY and cost benefits due to 
fewer side effects were even smaller (and thus not included 
in scenario analyses).
4  Discussion
In this model, the base-case ICER for acalabrutinib versus 
ibrutinib was £61,941/QALY, with 3.44 incremental QALYs 
and incremental costs of £213,339. This indicated that, even 
with a price equal to that of ibrutinib, acalabrutinib was 
not cost effective with a WTP threshold of £50,000. The 
probability of acalabrutinib being cost effective declined 
with greater efficacy. This finding is explained by the fact 
that longer PFS led to disproportionally higher costs, even 
though OS was also prolonged.
In the deterministic analysis, all parameters associated 
with PFS and OS had significant impact on the ICER. 
Parameters that had little impact were all one-off param-
eters (AEs, death costs) and parameters associated with the 
PPS state. Apparently, subsequent treatment choices do not 
greatly affect the cost effectiveness of acalabrutinib.
A price for acalabrutinib higher than ibrutinib, with a 
threshold of £50,000/QALY, would not lead to a cost-effec-
tive scenario. This indicates that, even though acalabrutinib 
would show good survival benefits, reimbursement for a 
higher price remains unlikely, impeding patient access. With 
treatment costs set at the base case, neither ibrutinib nor 
acalabrutinib was cost effective in the PFS state. However, 
the deterministic sensitivity analysis clarified that treatment 
costs have a large impact on the ICER. Thus, a cost reduction 
may potentially lead to time spent the PFS state being cost 
effective, which would greatly alter the cost effectiveness of 
both treatments. Indeed, in the tested scenario where both 
drug costs were minimal (with the rest of the parameters at 
base case), the ICER was £44,000/QALY.
For decision purposes, the cost effectiveness of an expen-
sive treatment in a certain health state can be roughly esti-
mated from its treatment costs and the utility in that state. 
If this estimate greatly exceeds the threshold, a modelling 
exercise may be redundant. However, as our analysis shows, 
modelling may still be very useful to provide insight into 
the relative effects of all parameters and their relevance to 
the ICER. When varied between their plausible bounds, 
improvements in PFS and OS led to opposite effects on the 
ICER. The relationship between PFS, OS and the ICER is 
often not straightforward within the context of an incre-
mental analysis. For example, when costs occur during 
PFS that are higher than the WTP threshold, the moderate 
QALY improvement associated with prolonged PFS may 
not offset these costs if prolonged PFS does not translate 
to prolonged OS. A positive correlation may exist, but pre-
vious publications have highlighted that these correlations 
are very inconsistent between and within different cancer 
types [29]. In this NICE decision support unit publication, 
it was furthermore deemed unclear how evidence support-
ing a correlation should be quantitatively implemented in 
a cost-effectiveness model. Thus, our primary assumption 
was independent of PFS and OS, but we ran scenario analy-
ses assuming dependence through sampling from a shared 
random number. It should be noted that this was possible 
because an exponential curve was implemented for both 
survival curves. If one of the curves had been parameter-
ised differently (e.g. Weibull), this approach would not have 
been viable. Correlating PFS and OS changed the shape of 
the cost-effectiveness plane, but it did not greatly impact 
the probability of the treatment being cost effective. How-
ever, the impact of correlation between PFS and OS may be 
greater for other drugs or in different disease areas. For early 
cost-effectiveness models, when information on the relation 
between PFS and OS is relatively sparse, we strongly advise 
testing the effects of correlation between survival curves in 
scenario analyses.
Recent research has shown that OS was included as a 
primary outcome in studies in only 18/68 (26%) of drug 
indications, whereas PFS accounted for another 31 (46%) 
and response rates for 11 (16%) [30]. For drug indications 
that lacked data on OS at time of approval, after a median 
follow-up of 5.4 years after market entry, only 7% were sub-
sequently shown to extend life. Our findings emphasise that 
this lack of demonstrated OS benefit induces problems in 
reimbursement processes.
Acalabrutinib was approved by the US FDA for mantle 
cell lymphoma (MCL) via the accelerated approval pathway 
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based on benefit in overall response rate. Though treat-
ments for MCL and CLL differ, of interest is that our analy-
sis shows that the manufacturer would get the best price in 
CLL when they solely show benefit through better response 
rates and do not prove PFS benefit. Acalabrutinib is cur-
rently being investigated in several phase II and III clinical 
trials for first-line and subsequent treatment in CLL, MCL 
and at least eight other indications varying from rheumatoid 
arthritis to urothelial carcinoma [10]. Our analysis shows 
that perverse incentives might be present in reimbursement 
processes. Therefore, it is essential that stakeholders engage 
early and discuss adequate evidence-generation plans pro-
spectively based on scenario analyses such as the one pre-
sented here.
Fig. 4  Range of variation in incremental costs and quality-adjusted 
life-years due to each critical parameter throughout all scenarios. Acal 
acalabrutinib, B base case, B/N base case/minimum, B/X base case/
maximum, C costs, ibru ibrutinib, N minimum, OS overall survival, 
PFS progression-free survival, U utility, X maximum
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4.1  Strengths and Limitations
A strength of this research effort is that it establishes an 
indication of cost effectiveness well in advance of any reim-
bursement considerations for acalabrutinib. Additionally, 
our model is based on a previous submission to NICE and 
assesses the influence of each parameter in sensitivity and 
scenario analyses, leading to well-founded conclusions on 
each parameters’ relevance.
However, relying on a previous NICE submission has 
its caveats. The use of input parameter values provided for 
ibrutinib may lead to biased estimates. In the ibrutinib sub-
missions, resource use was estimated through expert opin-
ion. Furthermore, the public report of the NICE appraisal is 
redacted in many places, which made it hard to implement 
some of the features and numbers. For example, we had to 
estimate the survival curves from the published data because 
the parameters for the curves were redacted in the report. 
Additionally, the utility reported was established in patients 
in clinical trials that differed from those for acalabrutinib. 
The lack of mature data specifically for acalabrutinib led 
to larger uncertainties in cost-effectiveness estimates but is 
also an inherent limitation to early modelling. We provided 
extensive sensitivity and scenario analyses to limit these 
risks.
Additionally, as mentioned, survival benefit was extracted 
from published phase I/II (acalabrutinib) and III (ibrutinib) 
studies. Several valid methods exist to estimate individual 
patient data from published Kaplan–Meier curves, which all 
vary slightly [21, 31, 32]. We chose the method developed 
by Hoyle and Henley [21] but others may also have been 
appropriate [33]. All of them represent an approximation 
of individual patient data (IPD) and thus have limitations. 
Unfortunately, IPD is not shared by the company.
While naive comparisons between trials have limitations, 
they are also common in the economic evaluation of phar-
maceutical products. Additionally, a previous study investi-
gated effect sizes between phase II and phase III and found 
that, for solid malignancies, phase III studies yielded on 
average a 12.9% lower objective response rate [34]. Though 
our analysis is not in solid malignancies and the endpoints 
used from the trials are survival endpoints, it should be 
noted from this previous research that comparing a phase II 
with a phase III trial may not be appropriate. However, we 
have performed extensive sensitivity and scenario analyses 
on the HRs provided by this comparison. To represent all 
possible outcomes for the survival benefit of acalabrutinib 
in comparison with ibrutinib, we chose the lower value for 
sensitivity analyses as no benefit (HR = 1.00).
Partitioned survival modelling itself has limitations, 
because modelling PFS and OS without modelling the 
underlying events may lead to over or underestimation of 
long-term survival. However, partitioned survival modelling 
is a common approach in oncology and is usually accepted 
by HTA bodies, as it was in the case of ibrutinib. Because 
survival in the PPS state was time dependent, we required 
the proportion of patients entering PPS from PFS. Our 
method to retrieve these events was similar to the ibrutinib 
submission in that it included correcting for background 
mortality. Still, the lack of actual information on progres-
sion of patients is a limitation to partitioned survival models.
We also did not include subsequent treatments other than 
rituximab + idelalisib, but results show that the nature and 
costs of subsequent treatment are practically irrelevant for 
cost-effectiveness estimates. Last, we also did not include 
ofatumumab as a comparator. Though the benefits of acala-
brutinib over ofatumumab may be different, it is likely that 
ibrutinib will be the primary comparator because it belongs 
to the same class.
4.2  Further Research
It was impossible to assess all scenarios when including all 
parameters (> 650 million scenarios). Automated analyses 
might provide additional insight into parameters that we 
excluded from scenario analysis. Finally, combining multi-
ple disease and treatment models leads to more insight into 
product dynamics and lifetime cost effectiveness. Such inter-
active models can accommodate the complexity of value-
based pricing within different indications for multiple drugs, 
leading to more appropriate reimbursement mechanisms.
5  Conclusion
In this early cost-utility analysis, survival benefits of acala-
brutinib do not result in a cost-effective scenario compared 
with ibrutinib. The relative and conflicting effects of OS, 
PFS, drug costs and utility during PFS show that determin-
ing the cost effectiveness of acalabrutinib without insight 
into all parameters complicates HTA decision making. Early 
assessment of the cost effectiveness of new products can 
support development choices and reimbursement processes 
through effective early dialogues between stakeholders, ulti-
mately improving patient access.
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